Literature DB >> 7977765

Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury.

I Kudoh1, J P Wiener-Kronish, S Hashimoto, J F Pittet, D Frank.   

Abstract

To determine whether exoenzyme S plays a role in alveolar epithelial injury, two parental strains of Pseudomonas aeruginosa, PAK and PA103, were tested that produced large quantities of exoenzyme S. Strains PAK and PA103 differ in the form of exoenzyme S they produce. Strain PAK produces a 53-kDa protein that does not possess ADP-ribosyltransferase activity and large quantities of a 49-kDa protein that expresses ADP-ribosyltransferase activity. Strain PA103 produces the 53-kDa protein and low amounts of exoenzyme S activity. A quantitative experimental protocol was used to measure the protein permeability of the alveolar epithelium and the dissemination of the bacteria to the pleural space and circulation. The results indicate that instillation of PAK and PA103 resulted in significant lung injury. Control experiments utilizing isogenic, exoenzyme S-deficient, regulatory mutants in the infection model reduced the lung injury and the dissemination of instilled bacteria. Taken together these results suggest that alveolar epithelial injury correlated with the production of the 53-kDa form of exoenzyme S or other coordinately regulated factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977765     DOI: 10.1152/ajplung.1994.267.5.L551

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  55 in total

1.  Differential sensitivity of human epithelial cells to Pseudomonas aeruginosa exoenzyme S.

Authors:  E M McGuffie; J E Fraylick; D J Hazen-Martin; T S Vincent; J C Olson
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Ras effector pathway activation by epidermal growth factor is inhibited in vivo by exoenzyme S ADP-ribosylation of Ras.

Authors:  M L Henriksson; R Rosqvist; M Telepnev; H Wolf-Watz; B Hallberg
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

3.  Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells.

Authors:  A J Vallis; V Finck-Barbançon; T L Yahr; D W Frank
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

4.  O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa.

Authors:  Karine Faure; David Shimabukuro; Temitayo Ajayi; Leonard R Allmond; Teiji Sawa; Jeanine P Wiener-Kronish
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 5.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

6.  Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro.

Authors:  N G Barclay; J C Spurrell; T F Bruno; D G Storey; D E Woods; C H Mody
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia.

Authors:  K Kooguchi; S Hashimoto; A Kobayashi; Y Kitamura; I Kudoh; J Wiener-Kronish; T Sawa
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Modulating Pathogenesis with Mobile-CRISPRi.

Authors:  Jiuxin Qu; Neha K Prasad; Michelle A Yu; Shuyan Chen; Amy Lyden; Nadia Herrera; Melanie R Silvis; Emily Crawford; Mark R Looney; Jason M Peters; Oren S Rosenberg
Journal:  J Bacteriol       Date:  2019-10-21       Impact factor: 3.490

9.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Authors:  Teiji Sawa; Emi Ito; Vinh Huu Nguyen; Matthew Haight
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.